Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors
Yolanda Piña,1 Samuel K Houston,1 Timothy G Murray,1 Tulay Koru-Sengul,2,3 Christina Decatur,1 William K Scott,4 Lubov Nathanson,4 Jennifer Clarke,2 Theodore J Lampidis,51Bascom Palmer Eye Institute, 2Department of Epidemiology and Public Health, 3Sylvester Comprehensive Cancer Center...
Main Authors: | Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-05-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/retinoblastoma-treatment-impact-of-the-glycolytic-inhibitor-2-deoxy-d--a9995 |
Similar Items
-
Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
by: Y Piña, et al.
Published: (2011-03-01) -
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors
by: Samuel K Houston, et al.
Published: (2011-01-01) -
Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma
by: Lonngi M, et al.
Published: (2013-02-01) -
Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
by: Nisha V. Shah, et al.
Published: (2014-01-01) -
Persistent Retinal Detachment in Retinoblastoma: The Challenges
by: Sophia El Hamichi, et al.
Published: (2020-01-01)